Medarex, Inc. and BioWa announced that they have entered into a license agreement which provides the Company with the first ever access to BioWa's COMPLEGENT Technology for enhancing the complement-dependent cytotoxicity (CDC) of select Medarex therapeutic antibodies.
There is no randomized data with a chemotherapy control supporting ipilimumab's survival-prolonging abilities.
Lead compund Ipilimumab performed below expectations, and may not be approved by the FDA for melanoma. Clinical trials for a similar drug tremelimumab, developed jointly with Pfizer has been suspended, further raising doubts.